Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Minority Interest (2021 - 2025)

Rani Therapeutics Holdings (RANI) has 5 years of Minority Interest data on record, last reported at -$4.1 million in Q3 2025.

  • For Q3 2025, Minority Interest fell 254.92% year-over-year to -$4.1 million; the TTM value through Sep 2025 reached -$4.1 million, down 254.92%, while the annual FY2024 figure was $1.5 million, 88.07% down from the prior year.
  • Minority Interest reached -$4.1 million in Q3 2025 per RANI's latest filing, down from -$3.6 million in the prior quarter.
  • Across five years, Minority Interest topped out at $80.3 million in Q3 2021 and bottomed at -$4.1 million in Q3 2025.
  • Average Minority Interest over 5 years is $25.5 million, with a median of $17.3 million recorded in 2023.
  • Peak YoY movement for Minority Interest: plummeted 44.72% in 2022, then plummeted 254.92% in 2025.
  • A 5-year view of Minority Interest shows it stood at $74.2 million in 2021, then tumbled by 49.9% to $37.1 million in 2022, then crashed by 66.14% to $12.6 million in 2023, then plummeted by 88.07% to $1.5 million in 2024, then crashed by 374.02% to -$4.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Minority Interest were -$4.1 million in Q3 2025, -$3.6 million in Q2 2025, and -$2.3 million in Q1 2025.